Cmd+Shift+7 initiates window mode recording
GIFOX 2 FREE
Cmd+Shift+6 initiates free selection mode recording Open up Gifox in any selection mode using preconfigured global shortcuts or customize them in preferences. Lockable aspect for fast selection restoreĪ set of capturing options accessible via preferences window let you explicitly control the recording and output.Īdvanced compression options provide complete control over the output quality and file size.īuilt-in editor provides the essential tools for fine-tuning your captured graphics and re-exporting them with different compression settings. Only selected window without any overlaps Pixel-sharp selection with accurate margins Free selection mode is also there for you – fast-select any area on the screen and hit record, like you used with the standard grab app / Cmd+Shift+4 command. Gifox introduces a completely new way of continuous screen capturing with window selection mode – you select a window and Gifox precisely records it even when it's moved or covered up by other windows. Animated instructions and bug reporting This study showed that B-GIFOX induced an ORR of 43% in patients with newly diagnosed NKTL however the median PFS was short at around 4months.Gifox is a beautifully designed and masterfully crafted app that records your screen into animated GIFs – the great alternative between static images and full-size videos. The following grade 3-4 toxicities were seen in at least 1 patient: thrombocytopenia (2), and tumor lysis syndrome (1). The following grade 1-2 toxicities were seen in at least 1 patient: anemia (7), thrombocytopenia (5), fever (3), ALT increase (3), nausea (2), vomiting (2), ALP increase (2), AST increase (1), alopecia (1), fatigue (1), and body ache (1). The median PFS was 4.3months (95% confidence interval 4.0-4.6 months) and the median OS was 14.9months (95% CI 0.6-29.2 months). The ORR was 42.8% one patient had a complete response, two had partial responses and 4 had progressive disease.
Six patients completed their planned treatment and one patient had disease progression through the first cycle of chemotherapy. Four patients had B symptoms and all but one patient had elevated LDH at diagnosis. The median age was 50 years (range: 34-61) and 5 (71.4%) were male. There were 7 patients recruited into the study 3 had stage II disease and 4 had stage IV disease. Both median PFS and OS were estimated using Kaplan-meier curves. OS was calculated from the start of treatment to the date of death or last follow-up. PFS was calculated from the start of treatment to the date of progression or last follow-up.
The primary objective was to estimate the overall response rates (ORR) and the secondary objectives were to estimate the progression free survival (PFS), overall survival (OS) and toxicities of this regimen. Dose and schedule of G, If and Ox were 1000mg/m2 on day 1, 5g/m2 on day 2 and 85mg/m2 on day 2 respectively. Intravenous B was dosed at 1.3mg/m2 on days 1, 4, 8, and 11 every 21 days. Patients with advanced stage disease were treated with 6 cycles of B-GIFOX. Patients with stage IB/IX or II were treated with 4 cycles of B-GIFOX followed by radiotherapy. Patients with histologically confirmed NKTL with stage IB or bulky(X) and stage II-IV disease were included. This was an open-labelled prospective phase II study approved by the institutional review board. Hence we conducted a study to evaluate the clinical efficacy of B-GIFOX in patients with newly diagnosed NKTL. We have also previously published a patient with relapsed NKTL that was successfully treated with GIFOX therapy. Further, drug testing in mouse NKTL xenograft suggest gemcitabine (G), oxaliplatin (ox) and ifosfamide (if) were effective in inducing tumor regression. Bortezomib (B) is a potent and reversible proteasome inhibitor which has shown single agent activity in preclinical models of NKTL in vitro and in vivo. Gene expression profiling of NKTL revealed overexpression of NF-kB. Natural-killer/T-cell lymphoma (NKTL) is a subtype of non-Hodgkin's lymphoma with poor response to conventional chemotherapy.
0 kommentar(er)
